Direxion Daily S&P Biotech Bull 3X Shares LABU
260.63 USD +19.45 (+8.06%)
At closeNov 4, 2026, 5:32 PM EST
260.10 -0.53 -0.20%
After hours · Nov 4, 5:32 PM ET
230.81 Day range 261.43
108.90 52-week range 341.93
- YTD
- +63.52%
- 1 year
- +126.06%
- Market cap
- 1.29B
- YTD return
- +63.52%
- 1-year return
- +126.06%
- Volume
- 409.96K
- Avg volume
- 394.40K
- Open
- 255.96
- Previous close
- 241.18
- Day's range
- 230.81 – 261.43
- 52-week range
- 108.90 – 341.93
1D +18.03 (+7.48%)
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 0
- Total debt
- 0
- Return on equity
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 258.08
- 200-day average
- 217.21
Next earnings
Consensus EPS estimate 0.00.
About Direxion Daily S&P Biotech Bull 3X Shares
The fund, under normal circumstances, invests at least 80% of its net assets in financial instruments, such as swap agreements, securities of the index, and ETFs that track the index, that, in combination, provide 3X daily leveraged exposure to the index, consistent with the fund's investment objective. The index is designed to measure the performance of the biotechnology sub-industry based on the Global Industry Classification Standards ("GICS"). The fund is non-diversified.
News
Why $55 Million Flowed Into a Triple-Leveraged Biotech ETF Worth Less Than $600 Million 
Biotech's Rebound Reality: Surging M&A Deals Meet Deep Retail Skepticism 
LABU Could Rip Higher if Biotech Finally Gets Its Long-Awaited Breakout 
Equal-Weight ETFs Are the Play for Small-Cap Drug Development. Here's How to Position Now 
34,270 Shares in Direxion Daily S&P Biotech Bull 3x Shares $LABU Purchased by JPMorgan Chase & Co. 
Direxion Daily S&P Biotech Bull 3x Shares (NYSEARCA:LABU) Shares Gap Down – Here’s Why 
Triple-Leveraged Biotech ETF Doubles as Regulatory Winds Shift in 2026 
Direxion Daily S&P Biotech Bull 3x Shares (NYSEARCA:LABU) Hits New 1-Year High – What’s Next? 
Navigate Biotech's Crosscurrents With Direxion's LABU And LABD ETFs 
Direxion Daily S&P Biotech Bull 3x Shares (NYSEARCA:LABU) Reaches New 52-Week High – What’s Next?
Your note
Sign in to keep a note on LABU — it syncs with the Stock Master app.